Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after progression on anti-PD-L1 therapy and chemotherapy	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Dostarlimab (TSR-042; Jemperli)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2024	View \| Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Durvalumab for limited stage small-cell lung cancer after 1 therapy	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab in addition to platinum based chemoradiation therapy for treating non-small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Durvalumab in combination with Tremelimumab and Standard of Care Chemotherapy for EGFR Negative, ALK Negative Metastatic NSCLC– First Line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab with tremelimumab for limited stage small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download